Related Experiment Video
Updated: Aug 1, 2026
10:18
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
First-line treatment in lymphomatoid papulosis: a retrospective multicentre study
R Fernández-de-Misa1, B Hernández-Machín2, O Servitje3
1Department of Dermatology and Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
Clinical and Experimental Dermatology
|October 11, 2017
Summary
Treatment for lymphomatoid papulosis (LyP) shows variable response, with phototherapy offering longer disease-free survival (DFS) despite similar complete response rates. Early relapse is linked to Type A LyP and treatments other than phototherapy.
Area of Science:
- Dermatology
- Oncology
- Clinical Medicine
Background:
- Limited data exist on treatment response in lymphomatoid papulosis (LyP).
- Assessing real-world clinical practice for LyP is crucial.
Purpose of the Study:
- To evaluate the daily clinical approach to LyP.
- To determine the efficacy of first-line treatments for LyP.
Main Methods:
- Retrospective study involving 252 patients diagnosed with LyP.
- Analysis of treatment patterns and patient outcomes.
Main Results:
- Topical steroids, methotrexate, and phototherapy were common first-line treatments.
- Complete response (CR) rates were similar across treatments, but phototherapy yielded significantly longer disease-free survival (DFS).
- Type A LyP variant and non-phototherapy treatments were associated with higher risks of early relapse.
Conclusions:
- Topical steroids, phototherapy, and methotrexate are frequently used first-line LyP treatments.
- Phototherapy demonstrates superior DFS compared to other first-line options.
- Early relapse risk is elevated in Type A LyP and with topical steroid or methotrexate use.
